Track the 한스바이오메드 stock price and the full directors' dealings record of the company, a listed issuer based in South Korea. Shares are listed on KR KR, under the supervision of DART (FSS). Operating in the Health Care sector, 한스바이오메드 has published 32 reports. The latest transaction was filed on 2 July 2026 (Sale). Among the most active insiders: 오스템임플란트. Every trade is openly available.
32
Insider Decl.
n/a
Thresholds
n/a
17 ops.
Buy Volume
n/a
7 ops.
Sell Volume
12Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Hans Biomed is a company specializing in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative biomedical solutions.